Inhibition of human anthracycline reductases by emodin - A possible remedy for anthracycline resistance

Toxicology and Applied Pharmacology
Jan HintzpeterEdmund Maser

Abstract

The clinical application of anthracyclines, like daunorubicin and doxorubicin, is limited by two factors: dose-related cardiotoxicity and drug resistance. Both have been linked to reductive metabolism of the parent drug to their metabolites daunorubicinol and doxorubicinol, respectively. These metabolites show significantly less anti-neoplastic properties as their parent drugs and accumulate in cardiac tissue leading to chronic cardiotoxicity. Therefore, we aimed to identify novel and potent natural inhibitors for anthracycline reductases, which enhance the anticancer effect of anthracyclines by preventing the development of anthracycline resistance. Human enzymes responsible for the reductive metabolism of daunorubicin were tested for their sensitivity towards anthrachinones, in particular emodin and anthraflavic acid. Intense inhibition kinetic data for the most effective daunorubicin reductases, including IC50- and Ki-values, the mode of inhibition, as well as molecular docking, were compiled. Subsequently, a cytotoxicity profile and the ability of emodin to reverse daunorubicin resistance were determined using multiresistant A549 lung cancer and HepG2 liver cancer cells. Emodin potently inhibited the four main human daunoru...Continue Reading

References

May 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·R D OlsonR J Boucek
May 1, 1997·Pharmacology & Toxicology·D Pröpper, E Maser
Jul 1, 1998·British Journal of Pharmacology·N Venkatesan
Feb 29, 2000·British Journal of Pharmacology·N VenkatesanV Arumugam
Jan 13, 2001·Chemico-biological Interactions·G L Forrest, B Gonzalez
Jan 25, 2002·IUBMB Life·A MordenteG Minotti
Jul 21, 2004·Journal of Computational Chemistry·Eric F PettersenThomas E Ferrin
Apr 1, 2005·PLoS Biology·Masahiro TanakaCynthia L Adams
Jun 20, 2006·Seminars in Oncology·Steven E Lipshultz
Oct 13, 2006·Cell Biology and Toxicology·P MennaE Salvatorelli
May 23, 2007·Expert Opinion on Pharmacotherapy·Elly BarrySteven E Lipshultz
Feb 16, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Onkar S BainsK Wayne Riggs
Mar 7, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ryan H TakahashiK Wayne Riggs
Jun 27, 2008·Chemico-biological Interactions·Magnus CarlquistMarie F Gorwa-Grauslund
Aug 30, 2008·Chemico-biological Interactions·Martina GavelováLenka Skálová
Dec 9, 2008·Chemico-biological Interactions·Yasser El-HawariEdmund Maser
Feb 11, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Onkar S BainsK Wayne Riggs
Dec 17, 2009·The Journal of Pharmacology and Experimental Therapeutics·Onkar S BainsK Wayne Riggs
Aug 5, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Weixue HuangLong Yu
Sep 15, 2010·The Journal of Pharmacology and Experimental Therapeutics·Onkar S BainsK Wayne Riggs
Feb 8, 2011·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Leila HosseinzadehGholamreza Karimi
Apr 26, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Haoran QianXianfa Wang
Jun 1, 2011·Nucleic Acids Research·Aurélien GrosdidierOlivier Michielin
Jun 7, 2011·Toxicology and Applied Pharmacology·Linlin ZhongDeliang Cao
Jan 4, 2012·Cancer Chemotherapy and Pharmacology·Mikkel Krogh-MadsenPer Hartvig Honoré
Feb 22, 2012·Indian Journal of Pharmacology·Agadihiremath Vishwanatha SwamyDonnahalli V Manjula
Jul 17, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Elisabeth CourcotJean-Marc Lo-Guidice

❮ Previous
Next ❯

Citations

Jun 3, 2021·Cancers·Esra Küpeli AkkolRaffaele Capasso
Jun 3, 2021·Metabolites·Satoshi EndoToru Nishinaka
Jul 28, 2021·Pharmacological Reviews·Trevor M PenningTea Lanišnik Rižner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.